Evidence map›Paper›PMID 26376476›Full record

ReviewCurrent opinion in gastroenterology2015

Gastroduodenal mucosal defense mechanisms.

Hyder Said, Izumi Kaji, Jonathan D Kaunitz

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Influence ofFrontiers in veterinary science · 2020
    Article
  4. Review
  5. Eicosanoids in the gastrointestinal tract.British journal of pharmacology · 2019
    Review
  6. Article
  7. Xenin Augments Duodenal Anion Secretion via Activation of Afferent Neural Pathways.The Journal of pharmacology and experimental therapeutics · 2017
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hyder SaidaResearch and Medical Services, VA Medical Center, West Los Angeles bCollege of Letters and Sciences cDepartment of Medicine dDepartment of Surgery, University of California, Los Angeles, California, USA.
Izumi Kaji
Jonathan D Kaunitz
West Los Angeles College · US

Funding

Duodenal Muscosal Defense MechanismsR01DK054221 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAUNITZ, JONATHAN D. · 1999 to 2016
$4.4M
BLRD VA I01 BX001245Intramural VA VA999999NIDDK NIH HHS R01 DK054221
6 · The paper itself

Abstract

purpose of reviewTo highlight recent developments in the field of gastroduodenal mucosal defense with emphasis on lumen-gut interactions. RECENT

findingsThere has been a growing interest in the physiological functions of luminal chemosensors present from tongue to colon that detect organic molecules in the luminal content associated with nutrient ingestion, usually associated with specialized cells, in particular the enteroendocrine cells. These receptors transduce the release of peptide hormones, in particular proglucagon-derived products such as the glucagon-like peptides (GLPs), which have profound effects on gut function and on metabolism. Luminal chemosensors transduce GLP release in response to changes in the cellular environment, as part of the mechanism of nutrient chemosensing. GLP-2 has important trophic effects on the intestinal mucosa, including increasing the proliferation rate of stem cells and reducing transmucosal permeability to ions and small molecules, in addition to increasing the rate of duodenal bicarbonate secretion. GLP-1, although traditionally considered an incretin that enhances the effect of insulin on peripheral tissues, also has trophic effects on the intestinal epithelium. SUMMARY: A better understanding of the mechanisms that mediate GLP release can further illuminate the importance of nutrient chemosensing as an important component of the mechanism that mediates the trophic effects of luminal nutrients. GLP-1 and GLP-2 are already in clinical use for the treatment of diabetes and intestinal failure. Improved understanding of the control of their release and their end-organ effects will identify new clinical indications and interventions that enhance their release.

Indexed as

Bile Acids and SaltsChemoreceptor CellsDuodenumGastric MucosaGastrointestinal DiseasesGlucagon-Like PeptidesHumansIntestinal MucosaNutritional Physiological PhenomenaReceptors, G-Protein-CoupledBile Acids and SaltsGlucagon-Like PeptidesReceptors, G-Protein-Coupled

Identifiers

PMID26376476
PMCPMC4711914
OpenAlexW2444131120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.